See more : Peace & Living Public Company Limited (PEACE.BK) Income Statement Analysis – Financial Results
Complete financial analysis of GH Research PLC (GHRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GH Research PLC, a leading company in the Biotechnology industry within the Healthcare sector.
- Bilibili Inc. (9626.HK) Income Statement Analysis – Financial Results
- Ameren Illinois Company (AILLI) Income Statement Analysis – Financial Results
- Veritec, Inc. (VRTC) Income Statement Analysis – Financial Results
- DGR Global Limited (DGR.AX) Income Statement Analysis – Financial Results
- Trident Limited (TRIDENT.NS) Income Statement Analysis – Financial Results
GH Research PLC (GHRS)
About GH Research PLC
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 315.00K | 47.00K | 19.00K | 0.00 | 0.00 |
| Gross Profit | -315.00K | -47.00K | -19.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 29.79M | 20.48M | 8.55M | 338.00K | 296.00K |
| General & Administrative | 11.30M | 10.07M | 6.55M | 108.00K | 14.00K |
| Selling & Marketing | 99.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.12M | 10.07M | 6.55M | 108.00K | 14.00K |
| Other Expenses | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 41.22M | 30.55M | 15.10M | 446.00K | 310.00K |
| Cost & Expenses | 41.22M | 30.55M | 15.10M | 446.00K | 310.00K |
| Interest Income | 1.89M | 858.00K | 9.00 | 0.00 | 0.00 |
| Interest Expense | 723.00K | 0.00 | 9.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 315.00K | 47.00K | 19.00K | 446.00K | 310.00K |
| EBITDA | -41.15M | -30.63M | -15.08M | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -41.22M | -30.55M | -15.10M | -446.00K | -310.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 5.64M | 8.10M | 5.90M | 0.00 | 0.00 |
| Income Before Tax | -35.59M | -22.46M | -9.20M | -446.00K | -310.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -15.32M | 9.00K | -205.30K | -310.00 |
| Net Income | -35.59M | -7.14M | -9.21M | -446.00K | -310.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.68 | -0.14 | -0.18 | -0.01 | 0.00 |
| EPS Diluted | -0.68 | -0.14 | -0.18 | -0.01 | 0.00 |
| Weighted Avg Shares Out | 52.02M | 52.02M | 52.02M | 70.00M | 70.00M |
| Weighted Avg Shares Out (Dil) | 52.02M | 52.02M | 52.02M | 70.00M | 70.00M |
The 7 Most Promising Psychedelic Stocks to Buy in February
Psychedelic Sunday: Competitive Strategies
7 Short-Squeeze Stocks for Bold Contrarians to Consider
New Strong Buy Stocks for October 24th
Wall Street Analysts See a 262% Upside in GH Research PLC (GHRS): Can the Stock Really Move This High?
7 Psychedelics Stocks to Buy for a Big Drug Boom
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
GH Research Stock (GHRS): Why The Price Jumped Today
GH Research Announces Positive Trial Results For Treatment-Resistant Depression
GH Research Posts Data From Treatment-Resistant Depression Trial
Source: https://incomestatements.info
Category: Stock Reports